Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing revenue splits, consumables margins and the latest on Illumina鈥檚 GRAIL antitrust battle are scattered across hundreds of regulatory pages. If locating an Illumina annual report 10-K simplified or decoding segment data in a quarterly filing feels overwhelming, you are not alone.
Stock Titan delivers the antidote: AI-powered summaries turn raw EDGAR documents into plain language so you can move from question to answer in seconds. Whether you need an Illumina quarterly earnings report 10-Q filing, want Illumina insider trading Form 4 transactions, or prefer Illumina Form 4 insider transactions real-time alerts, every disclosure appears here moments after it hits the SEC. Our engine highlights where management discusses flow-cell demand, R&D tax credits or litigation updates and links directly to the cited page.
Use cases include:
- Benchmark consumable growth with our Illumina earnings report filing analysis.
- Track leadership moves via Illumina executive stock transactions Form 4 before material announcements.
- Navigate strategic announcements with Illumina 8-K material events explained.
- Review pay practices inside the latest Illumina proxy statement executive compensation section.
This hub answers popular investor questions like 鈥�Illumina SEC filings explained simply鈥� and 鈥�understanding Illumina SEC documents with AI.鈥� AG真人官方-time updates, concise red-flag summaries and downloadable spreadsheets mean you spend less time parsing accounting notes and more time deciding what Illumina鈥檚 breakthroughs mean for your portfolio.
Form 4 highlights: On 07/07/2025, 10% owner Shay Capital LLC disclosed the purchase of derivative securities in Tilly鈥檚, Inc. (NASDAQ: TLYS).
- Security acquired: 300 call options (right to buy) on Tilly鈥檚 common stock.
- Strike / conversion price: $2.50 per share.
- Underlying shares: Each contract represents 100 shares, totalling 30,000 shares of common stock.
- Expiration: 16 Jan 2026.
- Transaction code: P (open-market purchase).
- Cost of option: $0.25 per contract as reported.
- Post-transaction holdings: 300 derivative securities held directly by the reporting person.
The filing indicates increased bullish exposure by a large shareholder but involves derivatives rather than outright share purchases. No other non-derivative transactions were reported.
BJ鈥檚 Wholesale Club Holdings, Inc. (BJ) 鈥� Form 4 insider transaction
President & CEO Robert W. Eddy filed a Form 4 for trades executed on 1 July 2025. Mr. Eddy, who is also a director, sold a total of 17,900 BJ common shares in three market transactions:
- 7,308 shares at a weighted-average $106.73
- 9,894 shares at a weighted-average $107.27
- 698 shares at a weighted-average $108.03
The weighted-average sale price range spanned $105.98鈥�$108.07. After the sales, the CEO retains 368,333 shares held directly and 2,000 shares held indirectly through dependent children, leaving him with roughly 370k shares in total. The disposition represents 鈮�4.6&苍产蝉辫;% of his prior direct ownership.
No derivative securities were reported. The filing does not reference a Rule 10b5-1 trading plan, so the sales appear discretionary. Investors often watch C-suite sales for sentiment signals; however, the executive continues to hold a sizeable equity stake, which may temper negative interpretations.
Illumina has entered into a significant Stock Purchase Agreement with Standard BioTools to acquire SomaLogic and Sengenics entities for $350 million in cash, plus potential milestone payments of up to $75 million. The deal, announced June 22, 2025, includes Standard BioTools' aptamer-based and functional proteomics business, featuring KREX and Single SOMAmer technologies.
Key transaction details:
- Purchase includes SomaLogic Inc, Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd
- Deal includes transition services and license agreements
- Closing deadline set for March 23, 2026, with three possible 3-month extensions
- $14.5 million termination fee if deal fails due to regulatory clearance issues
The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Act clearance and regulatory approvals. This strategic acquisition significantly expands Illumina's presence in the proteomics market, though the company notes several risk factors including integration challenges and market uncertainties.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
What is Illumina Inc's core business?
How does Illumina generate revenue?
What industries does Illumina serve?
What distinguishes Illumina's technology in the genomics field?
How does Illumina contribute to personalized medicine?
What role does innovation play at Illumina?
Who are Illumina's key customers?
How does Illumina maintain its competitive position?
